Nplate (romiplostim) / Amgen, Kyowa Kirin - LARVOL DELTA

Unintended First-Trimester Exposure to Two Distinct Thrombopoietin Receptor Agonists in Consecutive Pregnancies Without Maternal or Fetal Harm. (PubMed, Turk J Haematol) - No abstract available

Journal • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

Successful Management of Relapsed Severe Immune Thrombocytopenia Using Avatrombopag: A Case Report. (PubMed, Case Rep Hematol) - "We report the case of a 37-year-old woman with relapsed severe ITP, unresponsive to corticosteroids, IVIG, rituximab, romiplostim, eltrombopag, vincristine, cyclosporine, and splenectomy. This case demonstrates the efficacy of avatrombopag in a patient unresponsive to multiple prior therapies, including other TPO-RAs and splenectomy. Further studies are warranted to determine optimal treatment sequencing and long-term outcomes for patients in this challenging subgroup."

Journal • Cardiovascular • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura

A Clinical Study Comparing Romiplostim and rhTPO for Platelet Engraftment after Umbilical Cord Blood Transplantation (ChiCTR) - P2 | N=60 | Not yet recruiting | Sponsor: TThe Seventh Affiliated Hospital of Sun Yat-sen University (Shenzhen); The Seventh Affiliated Hospital of Sun Yat-sen University (Shenzhen)

New P2 trial • Hematological Malignancies • Transplantation

A Multicenter, Single-Arm Study of Romiplostim N01 in Megakaryocytic Engraftment after Allogeneic Hematopoietic Stem Cell Transplantation for Bone Marrow Failure Diseases (ChiCTR) - P4 | N=35 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University

New P4 trial • Aplastic Anemia • Bone Marrow Transplantation • Hematological Disorders • Transplantation

Chemotherapy-Free Achievement of Minimal Residual Disease in a Jehovah's Witness Patient With Ph-Negative B-ALL. (PubMed, Am J Case Rep) - "Supportive care included epoetin alfa, romiplostim, iron, and vitamin supplementation. CONCLUSIONS This is the first known reported case that demonstrates the feasibility and effectiveness of a chemotherapy-free induction strategy using inotuzumab and blinatumomab for frontline treatment of Ph-negative B-ALL in Jehovah's Witness patients. It shows that MRD negativity can be safely achieved without cytotoxic chemotherapy or transfusion support and supports the use of the ALLIANCE A041703 trial regimen as a treatment model for this unique and underserved patient group."

Journal • Minimal residual disease • Acute Lymphocytic Leukemia • Atrial Fibrillation • B Acute Lymphoblastic Leukemia • Cardiovascular • Hematological Disorders • Hematological Malignancies • Hypertension • Leukemia • Oncology

ROMIPLOSTIM IN PEDIATRIC PATIENTS POST HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR EARLY PLATELET ENGRAFTMENT- AN OPEN LABEL RANDOMISED CONTROLLED TRIAL (EBMT 2026) - "Romiplostim was safe and well tolerated following pediatric HSCT. While it did not significantly shorten platelet engraftment time, the intervention group demonstrated higher platelet and neutrophil counts by day +28, particularly among allogeneic and malignant subgroups. These findings support the feasibility of romiplostim use post-HSCT and warrant larger multicenter trials to establish its efficacy in the pediatric population."

Clinical • Bone Marrow Transplantation • Pediatrics • Transplantation

A CASE OF RESOLVED SEVERE HEMATOLOGICAL TOXICITY AFTER ANTI-BCMA CAR-T THERAPY FOR MULTIPLE MYELOMA (EBMT 2026) - "Lymphodepleting therapy consisted of fludarabine 30 mg x m2 and cyclophosphamide 300 mg x m2 for three consecutive days.The CAR-T cell dose was 1.27 cells x 106/kg of patient body weight, the ratio of CD4+ to CD8+ cells was 1.15...Grade 3 CRS was detected on day 7, which required 2-fold administration of Tocilizumab at a dose of 8 mg/kg, vasopressor support, and respiratory support... Despite achieving deep durable responses in multiple myeloma, CAR-T therapy may be associated with severe and prolonged hematological toxicity requiring complex and long-term therapy."

Clinical • Conjunctivitis • Cytomegalovirus Infection • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Multiple Myeloma • Neutropenia • Ocular Infections • Ocular Inflammation • Ophthalmology • Rare Diseases • Respiratory Diseases • Thrombocytopenia • CD4

Romiplostim N01 for the treatment of cancer treatment-induced thrombocytopenia (ChiCTR) - P=N/A | N=950 | Not yet recruiting | Sponsor: Yidu Central Hospital of Weifang City; Yidu Central Hospital of Weifang City

New trial • Oncology • Thrombocytopenia

Amgen...announced financial results for the fourth quarter and full year of 2025 versus the comparable periods in 2024. (PRNewswire) - "Nplate (romiplostim) sales increased 14% year-over-year to $385 million in the fourth quarter...IMDELLTRA (tarlatamab-dlle)/IMDYLLTRA™ (tarlatamab) generated $234 million of sales in the fourth quarter....MVASI (bevacizumab-awwb) sales increased 9% year-over-year to $188 million in the fourth quarter..."

Sales • Cervical Cancer • Epithelial Ovarian Cancer • Fallopian Tube Cancer • Glioblastoma • Immune Thrombocytopenic Purpura • Non Small Cell Lung Cancer • Ovarian Cancer • Peritoneal Cancer • Renal Cell Carcinoma • Small Cell Lung Cancer

Single-center clinical study on the efficacy and safety of romiplostim N01 in promoting platelet engraftment after hematopoietic stem cell transplantation (ChiCTR) - P=N/A | N=88 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Guilin Medical University; The First Affiliated Hospital of Guilin Medical University

New trial • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • NKG2D

High-Dose Romiplostim (N01) Monotherapy for Aplastic Anemia with Specific Gene Mutations: A Prospective Clinical Study (ChiCTR) - P3 | N=60 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Zhejiang Chinese Medical University; The First Affiliated Hospital of Zhejiang Chinese Medical University

New P3 trial • Anemia • Aplastic Anemia • Hematological Disorders

Comparison of the real-world efficacy and safety of romiplostim and recombinant human thrombopoietin (rhTPO) in chemotherapy-induced thrombocytopenia. (PubMed, BMC Cancer) - No abstract available

Journal • Real-world evidence • Hematological Disorders • Oncology • Solid Tumor • Thrombocytopenia

To Observe the Efficacy of Romiplostim N01 in Promoting Platelet Engraftment and Treating Thrombocytopenia After HSCT (ChiCTR) - P4 | N=240 | Not yet recruiting | Sponsor: Wuhan Childrens Hospital; Wuhan Childrens Hospital

New P4 trial • Bone Marrow Transplantation • Hematological Disorders • Thrombocytopenia • Transplantation

EFFICACY OF ROMIPLOSTIM ON HASTENING PLATELET COUNT RECOVERY IN POST-TRANSPLANT PATIENTS: A SINGLE-CENTER EXPERIENCE (EBMT 2026) - "Romiplostim administration (2-3 mcg/kg, D+5 to D+10) did not significantly hasten platelet engraftment in this cohort. None of the patients experienced any adverse effects from romiplostim. However, amongst patients who had a later engraftment, there was a trend toward benefit from romiplostim."

Clinical • Post-transplantation • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Hepatology • Lymphoma • Thrombocytopenia • Transplantation

A Retrospective Study of Bloodless Administration of Cellular Therapy in a Community Medical Center in an Outpatient and Inpatient setting: Patient Characteristics and Outcomes (TCT-ASTCT-CIBMTR 2026) - "Tranexamic acid, romiplostim and Epoetin alfa-epbx support are allowed. In this retrospective cohort of patients receiving ASCT or CarT under a bloodless therapy protocol, we have seen excellent cell recovery, toxicity, and 30-day mortality outcomes in both BL-ASCT and BL-CarT recipients. There is a trend for increased hospitalization in BLCT, largely due to inpatient administration of product and monitoring. We suggest that patients who cannot receive blood products should be considered for BL-ASCT or BL-CarT."

Retrospective data • Hematological Malignancies • Infectious Disease

Characterization of TPO Receptor Agonists for the Management of Thrombocytopenia after CAR T-cell Therapy (TCT-ASTCT-CIBMTR 2026) - "Romiplostim was used in 27 of 28 (96%) TPO-RA recipients...3 . Describe the real-world utilization patterns of TPO-RAs in CAR T-cell patients."

CAR T-Cell Therapy • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Thrombocytopenia

A real-world study on the treatment of aplastic anemia with Romiplostim N01 (ChiCTR) - P4 | N=60 | Not yet recruiting | Sponsor: Hebei Province Hospital of Chinese Medicine; Hebei Province Hospital of Chinese Medicine

New P4 trial • Anemia • Aplastic Anemia • Hematological Disorders

A Single-Arm, Multicenter, Exploratory Study on the Efficacy and Safety of Romiplostim NO1 in Platelet Recovery After Autologous Hematopoietic Stem Cell Transplantation (ChiCTR) - P=N/A | N=50 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Bengbu Medical University; The First Affiliated Hospital of Bengbu Medical University

New trial • Bone Marrow Transplantation • Hematological Malignancies • Lymphoma • Multiple Myeloma • Oncology • Transplantation • CD34

A Prospective Multicenter Randomized Controlled Clinical Study on the Efficacy and Safety ofRomiplostim (N01) in the Prevention ofThrombocytopenia after Chemotherapy for Childhood Tumors (ChiCTR) - P=N/A | N=120 | Not yet recruiting | Sponsor: The First Affiliated Hospital,Sun Yat-sen University; The First Affiliated Hospital,Sun Yat-sen University

New trial • Hematological Disorders • Oncology • Pediatrics • Thrombocytopenia

EFFICACY AND SAFETY OF ROMIPLOSTIM VERSUS RECOMBINANT HUMAN THROMBOPOIETIN (RHTPO) FOR HEMATOPOIETIC RECONSTRUCTION IN PATIENTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (ASCT) (EBMT 2026) - "In ASCT patients, Romiplostim is non-inferior to rhTPO regarding primary efficacy endpoints for hematopoietic reconstruction. Although the difference in engraftment time was not statistically significant, Romiplostim offers potential advantages in safety, convenience, and cost, and demonstrates a significant promoting effect on lymphocyte recovery, suggesting a more active role in accelerating immune reconstitution."

Clinical • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Lymphoma • Multiple Myeloma • Thrombocytopenia • Transplantation

FIRST REPORTED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) FOR RAD50 DEFICIENCY: INITIAL CLINICAL EXPERIENCE IN TWO PEDIATRIC PATIENTS (EBMT 2026) - "Within one year, bone marrow dysplasia with a del(5q) clone and blasts up to 6–7% evolved, consistent with MDS on the background of inborn error of immunity.Unrelated-donor allo-HSCT (conditioning regimen: fludarabine 150 mg/m², busulfan 4 mg/kg, ATG 5 mg/kg and rituximab 375 mg/m², with PTCy-based GVHD prophylaxis) was complicated by HHV-6 infection, severe infusion-associated rash, and subsequent graft rejection by day +60. Six months later a second haploidentical HSCT from the mother (conditioning regimen: fludarabine 150 mg/m², treosulfan 21 g/m², rituximab 375 mg/m² and alemtuzumab 0.4 mg/kg with PTCy-based GVHD prophylaxis) resulted in timely engraftment and was complicated by megakaryocytic lineage hypofunction, viral reactivation, COVID-19 infection, and mild skin GVHD.Case #2...The course was marked by transfusion dependence, recurrent infections and refractory thrombocytopenia despite romiplostim and eltrombopag therapy.At the age of..."

Clinical • Acute Kidney Injury • Aplastic Anemia • Bone Marrow Transplantation • CNS Disorders • Graft versus Host Disease • Hematological Disorders • Herpes Simplex • Immunology • Infectious Disease • Metabolic Disorders • Nephrology • Novel Coronavirus Disease • Pediatrics • Thrombocytopenia • Transplant Rejection • Transplantation • RAD50

ROMIPLOSTIM N01 FOR PROMOTING PLATELET ENGRAFTMENT AFTER ALLO-HSCT: INTERIM RESULTS OF A PHASE II EXPLORATORY TRIAL FROM NICHE COHORT (EBMT 2026) - "In summary, this interim analysis indicates that romiplostim N01 may accelerate platelet engraftment after allo-HSCT and demonstrated favorable tolerability and safety during the observation period; however, its clinical value requires confirmation in larger studies."

P2 data • Bone Marrow Transplantation • Hematological Malignancies • Thrombocytopenia

Preemptive Tocilizumab with Bispecific Antibodies in Relapsed-Refractory Multiple Myeloma: A Case Series (TCT-ASTCT-CIBMTR 2026) - "Teclistamab (Tec), Talquetamab (Tal), and Elranatamab (Elra) are bispecific antibodies (BsAbs) approved for relapsed-refractory Multiple Myeloma (RRMM) which target CD3 on T- cells and either BCMA or GPRC5D, depending on the BsAb...The only incident of CRS occurred with a single patient who developed grade 1 CRS on C1D3 which resolved after one dose dexamethasone 10 mg...Supportive care was given during treatment including filgrastim to maintain absolute neutrophil 1.00 K/mcl, epoetin alfa to maintain hemoglobin above 10g/dl, and romiplostim to maintain platelets above 50 K/mcl...3. Evaluate the potential role and clinical impact of preemptive tocilizumab administration in reducing the incidence and severity of CRS without compromising therapeutic response in patients receiving bispecific antibodies."

Clinical • Hematological Malignancies • Infectious Disease • Multiple Myeloma • IL6

A Multicenter, Prospective, Randomized Controlled Phase Ⅲ Study on Efficacy and Safety of Romiplostim versus Recombinant Human Thrombopoietin in the Treatment of Chemotherapy-Induced Thrombocytopenia in Patients with Non-Myeloid Malignancies. (ChiCTR) - P3 | N=196 | Not yet recruiting | Sponsor: The Third People’s Hospital of Chengdu; The Third People’s Hospital of Chengdu

New P3 trial • Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Thrombocytopenia

Bone Marrow Colony Stimulating Factors (CSF) and Stem Cell Therapy as Medical Countermeasures (MCM) for Treatment of Hematopoietic-Acute Radiation Syndrome: A Systematic Review. (PubMed, Disaster Med Public Health Prep) - "While studies looking at efficacy of CSFs given after 24 hours were limited, 2 studies included in this review showed that delayed administration of CSFs up to 120 hours may be beneficial compared to no treatment. Lack of standardization in experimental study design (e.g. radiation doses, animal species, interventions) between studies prevented direct comparisons using meta-analytic statistical approach."

Journal • Review